MediWound在澳大利亚获得了NexoBrid的TGA批准，用于成人和儿科热烧伤患者

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion

YAVNE, Israel, September 25, 2025 -- MediWound Ltd. (NASDAQ: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Australia's Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid®, the Company's innovative enzymatic therapy for the removal of eschar in both adult and pediatric patients with deep partial- and full-thickness thermal burns.

With this approval, NexoBrid is now authorized in 45 countries worldwide, reflecting its growing recognition as a new standard of care in burn management. MediWound's exclusive partner in Australia, Balance Medical, expects to initiate commercial launch in the fourth quarter of 2025.

MediWound's manufacturing expansion, on track for completion by year-end 2025, will support this launch and future global demand.